Edition:
United States

Profile: Senseonics Holdings Inc (SENS.N)

SENS.N on New York Stock Exchange

2.00USD
22 May 2019
Change (% chg)

-- (--)
Prev Close
$2.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
37,948
52-wk High
$5.27
52-wk Low
$1.93

Senseonics Holdings, Inc., incorporated on December 4, 2015, is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.

The Company's Eversense system consists of components, such as a sensor, which is inserted subcutaneously in the upper arm by a healthcare provider; an external removable smart transmitter that receives, assesses and relays the data from the sensor and also provides vibratory alerts, and a mobile application that receives data from the transmitter and provides real-time glucose readings, alerts and other data on the user's mobile device, such as a smartphone, Apple Watch or tablet. The smart sensor is designed to be inserted under the skin, either in the back of the upper arm or in the abdomen, and measures the glucose in the interstitial fluid. The removable smart transmitter is a rechargeable, external device that is worn over the sensor implantation site using a daily adhesive patch or band, such as an armband or waistband. Its mobile application is a software application that runs on both iPhone operating system (iOS) mobile devices, including iPhones, iPads and Apple Watches, and Android mobile devices. The mobile application receives information from the transmitter through Bluetooth and displays that information to the user.

The Company's Eversense system initially requires twice daily fingerstick calibrations. Further, upon receiving an alert from the CGM, a patient should confirm CGM measurements with test-strip measurements prior to self-medicating. The Company has initiated a pivotal trial in the United States.

The Company competes with Johnson & Johnson, Medtronic, Inc. and Tandem Diabetes Care, Inc.

Company Address

Senseonics Holdings Inc

20451 Seneca Meadows Pkwy
GERMANTOWN   MD   20876-7005
P: +1301.5157260
F: +1302.6555049

Company Web Links